Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Gastrointestinal Surgery
Erschienen in: Journal of Gastrointestinal Surgery 1/2011

01.01.2011 | Original Article

Knockdown of microRNA-21 Inhibits Proliferation and Increases Cell Death by Targeting Programmed Cell Death 4 (PDCD4) in Pancreatic Ductal Adenocarcinoma

verfasst von: Imran Bhatti, Andrew Lee, Victoria James, Richard I. Hall, Jonathan N. Lund, Cristina Tufarelli, Dileep N. Lobo, Michael Larvin

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aims to examine the expression of a panel of five microRNAs (miRNA) in pancreatic ductal adenocarcinoma (PDAC) and the functional effect of miR-21 inhibition in PDAC cell lines.

Background

miRNA are short, non-coding RNA molecules, which play important roles in several cellular processes by silencing expression of their target genes through translational repression or mRNA degradation. They are often aberrantly expressed in cancer, and this dysregulation can promote carcinogenesis by altering the expression of tumour suppressor or oncogenes.

Methods

miRNA expression levels were measured in 24 PDAC tumour/matched adjacent normal tissue samples and three PDAC cell lines using reverse transcription polymerase chain reaction. Levels of cell proliferation and death and expression of programmed cell death 4 (PDCD4; tumour suppressor) were studied in PDAC cells (MIA-Pa-Ca-2) in the absence or presence of a miR-21 inhibitor.

Results

PDAC primary tissues and cell lines displayed a consistent upregulation of miR-21 (P < 0.0001) and downregulation of both miR-148a (P < 0.0001) and miR-375 (P < 0.0001) relative to adjacent normal tissue. Furthermore, miR-21 levels in the primary tumours correlated with disease stage (P < 0.0001). Inhibition of miR-21 in MIA-Pa-Ca-2 PDAC cells led to reduced cell proliferation (P < 0.01) and increased cell death (P < 0.01), with simultaneous increase in levels of the tumour suppressor, PDCD4 (P < 0.01).

Conclusion

miRNA expression profiles may be used as biomarkers for detecting pancreatic cancer. Moreover, miR-21 could be a predictor of disease progression and a possible therapeutic target in part by upregulating PDCD4 in pancreatic cancer.
Literatur
1.
American Gastroenterological Association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology, 1999. 117(6): p. 1463–84.
2.
Pitt, H.A., Curative treatment for pancreatic neoplasms. Standard resection. Surg Clin North Am, 1995. 75(5): p. 891–904.
3.
Neoptolemos, J.P., et al., Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, 2001. 358(9293): p. 1576–85.PubMedCrossRef
4.
5.
Richter, A., et al., Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg, 2003. 27(3): p. 324–9.PubMedCrossRef
6.
Bae, Y.K. and M.M. Barr, Sensory roles of neuronal cilia: cilia development, morphogenesis, and function in C. elegans. Front Biosci, 2008. 13: p. 5959–74.PubMedCrossRef
7.
Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004. 116(2): p. 281–97.PubMedCrossRef
8.
Dillhoff, M., S.E. Wojcik, and M. Bloomston, MicroRNAs in solid tumors. J Surg Res, 2009. 154(2): p. 349–54.PubMedCrossRef
9.
Griffiths-Jones, S., et al., miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res, 2006. 34(Database issue): p. D140–4.
10.
Bushati, N. and S.M. Cohen, microRNA functions. Annu Rev Cell Dev Biol, 2007. 23: p. 175–205.PubMedCrossRef
11.
Schickel, R., et al., MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene, 2008. 27(45): p. 5959–74.PubMedCrossRef
12.
He, L., et al., A microRNA polycistron as a potential human oncogene. Nature, 2005. 435(7043): p. 828–33.PubMedCrossRef
13.
Ryu, J.K., et al., Aberrant microRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology, 2010. 10(1): p. 66–73.PubMedCrossRef
14.
du Rieu, M.C., et al., MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem, 2010. 56(4): p. 603–12.PubMedCrossRef
15.
Calin, G.A. and C.M. Croce, MicroRNA signatures in human cancers. Nat Rev Cancer, 2006. 6(11): p. 857–66.PubMedCrossRef
16.
Stahlhut Espinosa, C.E. and F.J. Slack, The role of microRNAs in cancer. Yale J Biol Med, 2006. 79(3–4): p. 131–40.PubMed
17.
Chan, J.A., A.M. Krichevsky, and K.S. Kosik, MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res, 2005. 65(14): p. 6029–33.PubMedCrossRef
18.
Ribas, J., et al., miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res, 2009. 69(18): p. 7165–9.PubMedCrossRef
19.
Meng, F., et al., Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology, 2006. 130(7): p. 2113–29.PubMedCrossRef
20.
Yao, Q., et al., MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem Biophys Res Commun, 2009. 388(3): p. 539–42.PubMedCrossRef
21.
Frankel, L.B., et al., Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem, 2008. 283(2): p. 1026–33.PubMedCrossRef
22.
Meng, F., et al., MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007. 133(2): p. 647–58.PubMedCrossRef
23.
Zhu, S., et al., MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem, 2007. 282(19): p. 14328–36.PubMedCrossRef
24.
Gabriely, G., et al., MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol, 2008. 28(17): p. 5369–80.PubMedCrossRef
25.
Lankat-Buttgereit, B. and R. Goke, The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biol Cell, 2009. 101(6): p. 309–17.PubMedCrossRef
26.
Jansen, A.P., et al., Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther, 2004. 3(2): p. 103–10.PubMed
27.
Ma, G., et al., [Expression of programmed cell death 4 and its clinicopathological significance in human pancreatic cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2005. 27(5): p. 597–600.PubMed
28.
Selaru, F.M., et al., MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology, 2009. 49(5): p. 1595–601.PubMedCrossRef
29.
Asangani, I.A., et al., MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene, 2008. 27(15): p. 2128–36.PubMedCrossRef
30.
Chen, Y., et al., MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett, 2008. 272(2): p. 197–205.PubMedCrossRef
31.
Ding, J., et al., Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol, 2010. 12(4): p. 390–9.PubMedCrossRef
32.
Bloomston, M., et al., MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA, 2007. 297(17): p. 1901–8.PubMedCrossRef
33.
Zhang, Y., et al., Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg, 2009. 33(4): p. 698–709.PubMedCrossRef
34.
35.
36.
37.
38.
Bhatti, I., et al., Small RNA: a large contributor to carcinogenesis? J Gastrointest Surg, 2009. 13(7): p. 1379–88.PubMedCrossRef
39.
Fabbri, M., et al., MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia, 2008. 22(6): p. 1095–105.PubMedCrossRef
40.
Chen, Y., et al., Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg, 2010. 14: p. 1170–9PubMedCrossRef
41.
Srinivasan, M., D. Sedmak, and S. Jewell, Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol, 2002. 161(6): p. 1961–71.PubMedCrossRef
42.
Cronin, M., et al., Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol, 2004. 164(1): p. 35–42.PubMedCrossRef
43.
Li, J., et al., Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol, 2007. 7: p. 36.PubMedCrossRef
44.
Wang, B., et al., TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene, 2010. 29(12): p. 1787–97.PubMedCrossRef
45.
Zhu, W., et al., miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer, 2010.
46.
James, T.A., et al., Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer, 2004. 101(12): p. 2722–6.PubMedCrossRef
47.
Farma, J.M., et al., PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol, 2008. 15(9): p. 2465–71.PubMedCrossRef
48.
Dillhoff, M., et al., MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg, 2008. 12: p. 2171–6.PubMedCrossRef
49.
Kloosterman, W.P. and R.H. Plasterk, The diverse functions of microRNAs in animal development and disease. Dev Cell, 2006. 11(4): p. 441–50.PubMedCrossRef
50.
Grimson, A., et al., MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell, 2007. 27(1): p. 91–105.PubMedCrossRef
51.
Chen, X., et al., Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 2008. 18(10): p. 997–1006.PubMedCrossRef
52.
Mitchell, P.S., et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 2008. 105(30): p. 10513–8.PubMedCrossRef
53.
Szafranska, A.E., et al., Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem, 2008. 54(10): p. 1716–24.PubMedCrossRef
54.
Wang, J., et al., MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila Pa), 2009. 2(9): p. 807–13.CrossRef
55.
56.
Corsten, M.F., et al., MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res, 2007. 67(19): p. 8994–9000.PubMedCrossRef
57.
Schetter, A.J., et al., Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res, 2009. 15(18): p. 5878–87.PubMedCrossRef
58.
Feber, A., et al., MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg, 2008. 135(2): p. 255–60; discussion 260.PubMedCrossRef
59.
Chan, S.H., et al., miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res, 2008. 28(2A): p. 907–11.PubMed
60.
Moriyama, T., et al., MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther, 2009. 8: p. 1067–74.PubMedCrossRef
61.
Motoyama, K., et al., Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol, 2010. 36(5): p. 1089–95.PubMed
62.
Mathe, E.A., et al., MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res, 2009. 15(19): p. 6192–200.PubMedCrossRef
63.
Tsukamoto, Y., et al., MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res, 2010. 70(6): p. 2339–49.PubMedCrossRef
Metadaten
Titel
Knockdown of microRNA-21 Inhibits Proliferation and Increases Cell Death by Targeting Programmed Cell Death 4 (PDCD4) in Pancreatic Ductal Adenocarcinoma
verfasst von
Imran Bhatti
Andrew Lee
Victoria James
Richard I. Hall
Jonathan N. Lund
Cristina Tufarelli
Dileep N. Lobo
Michael Larvin
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 1/2011
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-010-1381-x

Weitere Artikel der Ausgabe 1/2011

Journal of Gastrointestinal Surgery 1/2011 Zur Ausgabe

Original Article

A Case–Control Study of Laparoscopy-Assisted and Open Distal Gastrectomy for Advanced Gastric Cancer

Original Article

Adenosquamous Versus Adenocarcinoma of the Pancreas: A Population-Based Outcomes Analysis

Original Article

Mesenteric Vascular Thromboembolism in Inflammatory Bowel Disease: A Single Center Experience

Review Article

From Longitudinal Gastric Resection to Sleeve Gastrectomy—Revival of a Previously Established Surgical Procedure

Original Article

Detection of Lymph Node Involvement by Cytokeratin Immunohistochemistry is an Independent Prognostic Factor After Curative Resection of Esophageal Cancer

Case Report

Emergent Orthotopic Liver Transplantation for Hemorrhage from a Giant Cavernous Hepatic Hemangioma: Case Report and Review

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise